Skip to content
Medical Health Aged Care

Arthritis Australia welcomes funding for kids with arthritis

Arthritis Australia 2 mins read

Arthritis Australia has welcomed Australian Government funding announced in the federal budget for kids living with juvenile arthritis, including renewed funding for Arthritis Australia and its affiliates to expand access to juvenile arthritis kids camps.

“Our kids camps play a vital role in supporting children with juvenile arthritis and their families to navigate this misunderstood chronic condition,” said Arthritis Australia CEO Jonathan Smithers.

“This budget, which also includes support for early detection and diagnosis, shows a sustained commitment from the Government to provide better support for juvenile arthritis, and is a very welcome step towards implementing the recommendations of the Parliamentary Inquiry into childhood rheumatic illness.”

“We also strongly welcome cost of living measures to freeze indexation of Pharmaceutical Benefits Scheme copayments.”

“However, there are still major untapped opportunities to improve arthritis care that will ultimately reduce health system expenditure, such as the huge and growing cost of joint replacement surgery, one of the most expensive items in the health budget.”

“Three quarters of people with arthritis have at least one other chronic condition, and symptoms like pain and immobility are a major barrier to managing their overall health. They need better support at a much earlier stage, through multidisciplinary models of care that will be effective not just for arthritis and musculoskeletal conditions, but many other chronic diseases too.

“For conditions such as low back pain, we are seeing serious harms to desperate patients who are resorting to risky and ineffective surgery because the health system is not providing them with access to evidence based alternatives to manage their pain.”

“We call on the Government to take the opportunity presented by the refresh of the Chronic Disease Framework to invest in better care for arthritis and musculoskeletal conditions, which are the highest disability burden disease group.”

“We also want to see increased funding for research into high burden conditions like arthritis through the Medical Research Future Fund, and look forward to engaging with the Government on the development of a national research strategy.”

Arthritis and musculoskeletal conditions cost the health system almost $15 billion a year. Arthritis Australia recently released new research projecting over 5.3 million Australians will be living with arthritis by 2040, marking a sharp 31% increase from today’s figures. An overall loss of $9.4 billion in GDP has been projected in 2030 due to the impact of arthritis on the labour force via lost income, additional welfare payments, and lost taxation revenue.

 


About us:

About Arthritis Australia

Arthritis Australia is the peak national body for arthritis, advocating on behalf of around 4 million Australians living with arthritis, and working with many other arthritis organisations to deliver information and support to people living with more than 100 types of arthritis and musculoskeletal conditions. We are a leading non-government funder of arthritis research in Australia and advocate for policies, programs and funding initiatives that will improve the health and wellbeing of people living with arthritis. For more information visit: arthritisaustralia.com.au


Contact details:

Issued by Cube on behalf of Arthritis Australia. For more information, please contact: Anne-Marie Sparrow on 0417 421 560.

More from this category

  • Medical Health Aged Care
  • 13/09/2024
  • 12:40
Zenas BioPharma

Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. All of the shares are being offered by Zenas. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $225.0 million. Zenas’ common stock is expected to begin trading…

  • Medical Health Aged Care
  • 13/09/2024
  • 12:31
Dementia Australia

New report reinforces dementia as chronic disease of 21st century

Updates to the Dementia in Australia report, released today by the Australian Institute of Health and Welfare (AIHW), reinforce that dementia is an urgent public health issue. Dementia is the second leading cause of death in Australia, the leading cause of death of women, the second leading cause of disease burden overall, and the leading cause of burden for people aged 65 and over. Dementia Australia CEO Professor Tanya Buchanan saidthe report highlights the enormity and impact of dementia in Australia as the chronic disease of the 21st century. “Despite the growing number of Australians diagnosed with dementia – there…

  • Medical Health Aged Care, Science
  • 13/09/2024
  • 11:08
La Trobe University

Centre to play key role in global AI medical research

Artificial intelligence promises to unlock new cures for cancer and other diseases by revolutionising the speed, cost and availability of personally designed drugs and enabling these to be tested on “digital twins" before being given to patients. AI will enable broad-spectrum like chemotherapy to be replaced by these more personalised, better targeted treatments. Scientists at La Trobe University's new Australian Centre for Artificial Intelligence in Medical Innovation (ACAMI), launched today, will also apply AI techniques to mRNA therapy development to enable faster design of more precise and effective treatments. Vice-Chancellor Professor Theo Farrell said ACAMI would sit within La Trobe’s…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.